Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Cardiome Pharma Corp. (NASDAQ: CRME) shares soared 25.98 percent to close at $3.20 a share Thursday. The stock traded between $2.54 and $3.27 on volume of 419,964 shares traded. The company recently announced a commercialization agreement with Tzamal Medical Ltd., to sell and distribute BRINAVESS exclusively in Israel. Shares of Cardiome Pharma have gained approximately 66.0 percent year-to-date.
Get more information on Cardiome Pharma and free access to the in-depth equity report at: www.FiveStarEquities.com/CRME
Gentiva Health Services, Inc. (NASDAQ: GTIV) shares surged 11.49 percent to close at $12.42 a share Thursday. The stock traded between $11.28 and $12.53 on volume of 371,987 shares traded. The company announced that it has agreed to acquire Harden Healthcare Holdings, Inc. for approximately $408.8 million. Shares of Gentiva Health Services have gained approximately 24.0 percent year-to-date.
Get more information on Gentiva Health Services and free access to the in-depth equity report at: www.FiveStarEquities.com/GTIV
OraSure Technologies, Inc. (NASDAQ: OSUR) shares spiked 11.28 percent to close at $6.41 a share Thursday. The stock traded between $5.99 and $6.43 volume of 1.05 million shares traded. Raymond James analyst Nicholas Jansen has upgraded the company’s rating to "outperform" from “market perform”. Shares of OraSure Technologies have declined approximately 10.0 percent year-to-date.
Get more information on OraSure Technologies and free access to the in-depth equity report at: www.FiveStarEquities.com/OSUR
Transcept Pharmaceuticals Inc. (NASDAQ: TSPT) shares increased 4.74 percent to close at $3.76 a share Thursday. The stock traded between $3.64 and $3.90 on volume of 520,181 shares traded. Retrophin, Inc. has proposed to acquire all of the shares of Transcept common stock that it doesn't already own for $4.00 per share in cash. Shares of Transcept Pharmaceuticals have fallen approximately 15.0 percent year-to-date.
Get more information on Transcept Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/TSPT
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]